טוען...
Targeting of BMI-1 with PTC-209 inhibits glioblastoma development
Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor and refractory to existing therapies. The oncogene BMI-1, a member of Polycomb Repressive Complex 1 (PRC1) plays essential roles in various human cancers and becomes an attractive therapeutic target. Here we showed that BMI-...
שמור ב:
| הוצא לאור ב: | Cell Cycle |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6110607/ https://ncbi.nlm.nih.gov/pubmed/29886801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2018.1469872 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|